News Articles for Orthocell

Perth biomedical firm Orthocell has gained a toehold in China for its nerve repair product via a deal with a Hong Kong-based medical products distributor.

Orthocell has entered an MOU to secure exclusive distribution rights for Marine Biomedical's innovative bone substitute PearlBone, and lift its stake in the company to 12 per cent.

Murdoch-based Orthocell has announced plans to raise $30 million, as it aims to build further momentum behind its US ambitions.

PPS Water Group founder Matthew Rear has been named Australia's top services entrepreneur at the 2026 EY Entrepreneur Of The Year awards.

After a brief hiatus where Rebecca Tomkinson took over, John Van Der Wielen is back in his role as chair of the state government's Future Health Research and Innovation Fund Advisory Council.

WA biotech Orthocell has announced a promising new use case for its Remplir nerve regeneration product, this time in reducing post-surgical complications in prostate cancer sufferers.

WA's medical sector is anxiously awaiting fallout from the US's pharma tariffs, although impending changes could assuage US concerns.

Former deputy prime minister Kim Beazley has stepped down from his role with biotech upshot Orthocell, citing health concerns.

Perth medtech Orthocell has appointed a former Pilbara Minerals figure and ex-Olympian to its executive team.

A day after announcing a record quarterly revenue of $2.7 million, Perth medtech Orthocell has appointed a former Pilbara Minerals figure and ex-Olympian to its executive team.

Orthocell boss Paul Anderson has heralded the first surgical use of its Remplir nerve repair device in the US as a “significant milestone”.

The Perth biotech company has welcomed a US academic for a series of talks at universities across the country.

Murdoch-based Orthocell's push to expand the reach of its nerve repair product Remplir has continued, following news it has received regulatory approval in Hong Kong.

Orthocell boss Paul Anderson said the Murdoch-based biotech medical company is “well ahead” of its original targets in relation to US sales of its nerve repair product, Remplir.

Shares in Murdoch-based Orthocell rose by 15 per cent early on Wednesday, following news the biotech medical company had received regulatory approval to sell its nerve repair product in Canada.

Fresh from receiving clearance from the Food and Drug Administration to distribute its nerve repair product Remplir in the US earlier this month, Murdoch-based Orthocell has appointed an initial four distributors.

Orthocell has posted its fourth consecutive quarter of record revenue, as the regenerative medicine company continues to expand its reach around the globe.

John Van Der Wielen-chaired Orthocell has received another timely boost, as it aims to further a push into Latin America.

Orthocell has received clearance from the US-based Food and Drug Administration to begin selling its nerve repair product Remplir in the country.

Singapore's Health Science Authority has granted regulatory approval for John Van Der Wielen-chaired Orthocell for use of its dental membrane project, Striate+.

Murdoch-based medtech firm Orthocell has continued its expedited expansion push, following news it had lodged an application to sell its nerve repair project Remplir in Canada.

Kim Beazley-backed medtech company Orthocell has flagged an expedited expansion into several jurisdictions after strong early sales of its Remplir nerve repair technology.

Murdoch-based regenerative medicine company Orthocell has posted its third consecutive quarter of record revenue, as it gears up for a final approval from the US FDA for its Remplir nerve product.

Orthocell has submitted its application for US Food and Drug Administration approval for its Remplir nerve regeneration product, marking another moment in a year full of milestones.

Biotech firm Orthocell is a step closer to its nerve repair device Remplir being approved in the US, following the completion of its US regulatory study.

Orthocell has struck a deal with a medical equipment supply firm to distribute its nerve repair device in Singapore, sending the Perth company's shares up 26 per cent.

Perth-based biotechnology firm Orthocell has raised $17 million to take its Remplir nerve regeneration product to the world's biggest healthcare market.

Murdoch-based Orthocell has received regulatory approval to commence sales of Remplir in Singapore, as the listed biotech company posts a second consecutive quarter of record revenue.

A western suburbs research precinct will be turned into WA's biomedical hub in a move the state government hopes will enable more local manufacturing

Perth-founded biotech company Orthocell has received regulatory approval to commence sales of its guided bone regeneration product Striate+ in Canada.

Orthocell has reported a record revenue of $1.84 million in the recent quarter, with the biotech company's annual growth up by more than 30 per cent.

Having led multiple corporate transformation projects, John Van Der Wielen shares his thoughts on what works and what doesn't.

Biotechnology company Orthocell will raise $3.5 million, with proceeds put towards its international market expansion strategy.

Our weekly appointments wrap includes Di Bain, Rebecca Gravestock, Fiona Notley, Andrew Van Der Merwe, Kim Beazley, Felicity Gooding, Robert Ierace and Simon Theobald.

Former Western Australian governor Kim Beazley has joined the board of Murdoch-based biotechnology company Orthocell, chaired by John Van Der Wielen.

Our board moves wrap includes John Seton, Ricardo Garzon Rangel, Troy Hayden, Quinton Meyers, Chris Zielinski, Stewart Washer, Andrew Woskett, Patrick Burke, Jerry Monzu, and Craig McNab.

Medical implants and waste reduction are among the local uses for technology derived from the sea.

Our weekly appointments wrap includes Richard McLeod, Debra Sayce, Wayne Bull, Mark Barnaba, John Gelavis, Brad Royce, Fiona Wood, Don Pyke, Ronni Kahn and James Goth.

Our board moves wrap includes Lindiwe Mthimunye, Val Coetzee, Jonathan Velloza, John Welborn, Craig Mitchell, Andrew Tyrrell, Fiona Wood, Qi Xiao Zhou, Stewart Washer, Peter Harold, and Peter Venn.

Burns surgeon Fiona Wood has been appointed to the board of John Van Der Wielen-chaired biotechnology company Orthocell as it prepares for international commercialisation.